Bone Biologics Corp Stock Analysis
| BBLGW Stock | USD 15.00 0.00 0.00% |
Bone Biologics Corp is overvalued with Real Value of 14.4 and Hype Value of 21.36. The main objective of Bone Biologics stock analysis is to determine its intrinsic value, which is an estimate of what Bone Biologics Corp is worth, separate from its market price. There are two main types of Bone Biologics' stock analysis: fundamental analysis and technical analysis.
The Bone Biologics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Bone Biologics is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Bone Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. Bone Stock Analysis Notes
The company recorded a loss per share of 0.14. Bone Biologics Corp had not issued any dividends in recent years. The entity had 1:6 split on the 10th of June 2025. Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts. Bone Biologics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. For more info on Bone Biologics Corp please contact Jeffrey Frelick at 781 552 4452 or go to https://www.bonebiologics.com.Bone Biologics Corp Investment Alerts
| Bone Biologics Corp is not yet fully synchronised with the market data | |
| Bone Biologics Corp generated a negative expected return over the last 90 days | |
| Bone Biologics Corp has high historical volatility and very poor performance | |
| Bone Biologics Corp has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (4.11 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bone Biologics Corp has accumulated about 4.44 K in cash with (4.12 M) of positive cash flow from operations. | |
| Bone Biologics Corp has a frail financial position based on the latest SEC disclosures |
Bone Biologics Environmental, Social, and Governance (ESG) Scores
Bone Biologics' ESG score is a quantitative measure that evaluates Bone Biologics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Bone Biologics' operations that may have significant financial implications and affect Bone Biologics' stock price as well as guide investors towards more socially responsible investments.
Bone Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.06) | (1.12) | |
| Return On Capital Employed | (1.21) | (1.15) | |
| Return On Assets | (1.06) | (1.12) | |
| Return On Equity | (1.18) | (1.12) |
Management Efficiency
The company has return on total asset (ROA) of (0.7773) % which means that it has lost $0.7773 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.2948) %, meaning that it generated substantial loss on money invested by shareholders. Bone Biologics' management efficiency ratios could be used to measure how well Bone Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.12 in 2025. Return On Capital Employed is likely to climb to -1.15 in 2025. At this time, Bone Biologics' Other Assets are fairly stable compared to the past year. Debt To Assets is likely to climb to 347.01 in 2025, whereas Total Assets are likely to drop slightly above 2.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.30 | 2.41 | |
| Tangible Book Value Per Share | 2.30 | 2.41 | |
| Enterprise Value Over EBITDA | (1.27) | (1.34) | |
| Price Book Value Ratio | 2.46 | 2.58 | |
| Enterprise Value Multiple | (1.27) | (1.34) | |
| Price Fair Value | 2.46 | 2.58 | |
| Enterprise Value | 4.7 M | 8.1 M |
At Bone Biologics Corp, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Bone Biologics Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bone Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bone Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bone Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bone Biologics Outstanding Bonds
Bone Biologics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bone Biologics Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bone bonds can be classified according to their maturity, which is the date when Bone Biologics Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Bone Biologics Predictive Daily Indicators
Bone Biologics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bone Biologics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Bone Biologics Corporate Filings
| 3rd of July 2025 Other Reports | ViewVerify | |
| 30th of June 2025 Other Reports | ViewVerify | |
8K | 26th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
S1 | 24th of June 2025 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
8K | 6th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 30th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 12th of May 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 23rd of April 2025 Other Reports | ViewVerify |
About Bone Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Bone Biologics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bone shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Bone Biologics. By using and applying Bone Stock analysis, traders can create a robust methodology for identifying Bone entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Bone Biologics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Optimization Now
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk |
| All Next | Launch Module |
Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.